YOLFTbeta
NervGen Pharma Corp.

NervGen Pharma Corp.

NGEN · NASDAQ · Healthcare / Biotechnology

1.88USD+0.25 (+15.34%)

Price History

Full chart

Market Stats

Previous Close1.63
Open1.68
Day Range1.62 – 1.94
52-Week Range1.58 – 6.30
Volume1.99M
Market Cap208.59M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.56
Dividend Yield0.00%
Beta0.73
50-Day Avg1.91
200-Day Avg3.29

About

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Adam H. Rogers M.D.
  • Employees9
  • Headquarters112-970 Burrard Street, Vancouver, BC, Canada, V6Z 2R4, USA
  • Websitehttps://nervgen.com

Leadership

  • Dr. Adam H. Rogers M.D.President, CEO & Chairman
  • Dr. Harold Martin Punnett D.M.D.Co-Founder & Independent Director
  • Dr. Randall E. Kaye M.D.Chief Medical Advisor & Director · b. 1962
  • Dr. Keith A. Vendola M.B.A., M.D.Chief Financial Officer · b. 1972

Financials

Income Statement

Currency: CAD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-----0000
Cost of Revenue-19.70K39.26K39.73K42.95K114.10K145.01K83.74K-
Gross Profit--19.70K-39.26K-39.73K-42.95K-114.10K-145.01K-83.74K-
Operating Expense-1.33M10.09M11.18M12.87M22.71M17.63M24.83M-
Operating Income-11.98K-1.35M-10.13M-11.22M-12.91M-22.82M-17.78M-24.92M-25.08M
EBITDA-11.98K-1.33M-9.99M-11.17M-12.78M-19.92M-22.24M-23.91M-5.65M
Net Income-11.98K-1.35M-10.03M-11.21M-12.82M-20.54M-22.38M-23.99M-44.12M
R&D-777.93K6.62M6.14M6.88M16.43M8.00M15.66M13.91M
Interest Expense-----510.07K0--

Balance Sheet

Currency: CAD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets-3.09M6.95M6.69M18.03M23.67M13.24M19.47M23.21M
Total Liabilities-581.26K949.14K756.78K1.09M10.32M15.25M16.90M19.73M
Total Equity-2.51M6.00M5.93M16.95M13.34M-2.01M2.57M3.48M
Cash-2.47M4.22M5.61M17.06M22.25M11.66M17.26M22.07M
Total Debt-----280.96K197.21K105.53K8.37K
Net Debt--2.47M-4.22M-5.61M-17.06M-21.97M-11.46M-17.15M-22.06M

Cash Flow

Currency: CAD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.04M-8.31M-6.32M-8.33M-17.63M-11.30M-16.83M-19.50M
Investing Cash Flow-126.41K--3.43K-45.43K-20.92K-138.87K58.83K100.93K
Financing Cash Flow3.58M10.11M7.87M19.76M22.44M766.35K22.68M23.76M
Capital Expenditure003.43K2.77K20.92K5.63K00
Free Cash Flow-1.04M-8.31M-6.32M-8.33M-17.65M-11.30M-16.83M-19.50M
FCF to OCF100.00%100.00%100.05%100.03%100.12%100.05%100.00%100.00%

Earnings

Report DateJun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Aug 19, 2021Nov 19, 2021Feb 28, 2022May 12, 2022Aug 9, 2022Nov 14, 2022Mar 30, 2023May 15, 2023Aug 9, 2023Nov 9, 2023May 16, 2024Aug 22, 2024Nov 14, 2024May 15, 2025Aug 26, 2025Nov 25, 2025Mar 31, 2026May 18, 2026Aug 13, 2026Nov 12, 2026
EPS Estimate----------------------0.06-0.06-0.04-0.07-0.06-0.09-0.05
EPS Actual-0.04-0.06-0.08-0.05-0.06-0.05-0.10-0.05-0.06-0.07-0.07-0.08-0.10-0.05-0.07-0.06-0.06-0.05-0.03-0.08-0.05-0.04-0.09-0.04-0.27-0.07-0.37-
Surprise---------------------33.33%-50.00%4.19%-285.71%-11.79%-311.11%-
Timing---------------------Pre-marketPre-market-Pre-market-Pre-market-

Key Statistics & Ratios

Market Cap208.59M
Enterprise Value195.06M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book17.12
EPS-0.56
Book Value0.1158
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-32.25M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-757.48%
Return on Assets-37.70%
Shares Outstanding107.52M
Shares Float95.30M
Beta0.73
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
11.16%
Insiders
15.63%
Retail / Other
73.21%

Top Institutional Holders

  • Empery Asset Management, LP
    4.00M3.72%
  • Rock Springs Capital Management LP
    1.21M1.12%
  • Dafna Capital Management LLC
    1.05M0.98%
  • PFG Investments, LLC
    217.50K0.20%
  • Bank of America Corp
    200.66K0.19%
  • Marshall Wace Asset Management Ltd
    200.36K0.19%
  • Royal Bank of Canada
    171.96K0.16%
  • Quadrature Capital Limited
    134.52K0.13%
  • Bank of Montreal
    78.39K0.07%
  • Integrated Wealth Concepts LLC
    74.22K0.07%
  • BMO Capital Markets Corp.
    62.90K0.06%
  • CapTrust Financial Advisors
    62.37K0.06%
  • UBS Group AG
    61.52K0.06%
  • AXQ CAPITAL LP
    43.10K0.04%
  • Advisor Group Holdings, Inc.
    39.99K0.04%
  • Millennium Management LLC
    39.74K0.04%
  • GREAT VALLEY ADVISOR GROUP, INC.
    35.50K0.03%
  • Commonwealth Equity Services, LLC
    33.00K0.03%
  • Mckinley Carter Wealth Services Inc
    32.65K0.03%

Top Fund Holders

  • Fidelity Nasdaq Composite Index
    67.45K0.06%